Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Invest New Drugs. 2021 Jan 7;39(3):829–835. doi: 10.1007/s10637-020-01043-9

Table 2.

Prior treatments before pembrolizumab treatment

Patient Prior RT No. of prior cytoreductive surgeries No. of prior systemic therapies Prior systemic therapies1
1 Yes 5 7 1 – Letrozole2
2 – Carboplatin/paclitaxel, followed by anastrozole maintenance*
3 – Bevacizumab
4 – Leuprolide
5 – Tamoxifen
6 – Carboplatin/paclitaxel
7 – Lurbinectedin
2 No 2 7 1 – Carboplatin/paclitaxel2
2 – Carboplatin/paclitaxel/bevacizumab
3 – Bleomycin/etoposide/cisplatin
4 – Anastrozole*
5 – Leuprolide
6 – Megestrol
7 –Megestrol/tamoxifen
3 No 4 4 1 – Carboplatin/docetaxel*
2 – Carboplatin/paclitaxel
3 – Anastrozole
4 – Lurbinectedin
4 No 2 3 1 – Bleomycin/etoposide/cisplatin with exemestane2
2 – Carboplatin/paclitaxel followed by carboplatin/docetaxel*
3 – Lurbinectedin
5 No 2 10 1 – Carboplatin/paclitaxel2
2 – Carboplatin/paclitaxel
3 – Letrozole
4 – Leuprolide
5 – Bevacizumab
6 – Endoxifen*
7 – Temozolomide/methoxyamine
8 – Ixazomib/vorinostat
9 – Tamoxifen
10 – Lurbinectedin

RT = radiation therapy.

1

Lines of systemic therapy are ordered chronologically.

2

Postoperative adjuvant therapy following surgical staging.

*

Longest duration of disease control following first disease recurrence.